Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

SS Innovations Completes World's Longest Robotic Telesurgery

SS Innovations said it completed the world’s longest-distance robotic telesurgery, with a cardiac procedure carried out across about 12,500 miles, or 20,000 kilometers, of fiber network distance between Guyana and India.

The company said the new record more than doubled its prior longest telesurgery distance. The previous mark, also performed using the SSI Mantra system, connected Strasbourg, France to Indore, India over about 6,250 miles, or 10,000 kilometers.

Chief Executive Officer and cardiac surgeon Dr. Sudhir Srivastava remotely performed a left internal mammary artery takedown from Guyana using the SSI MantraSana tele-surgeon console, while the patient-side robotic setup was located in Indore, India. The company said the system operated with network latency of 290 to 300 milliseconds during the procedure.

The latest surgery brings the total number of cardiac telesurgeries performed with SSI Mantra to 22. SS Innovations said the SSI Mantra is the only surgical robotic system globally that has been used for cardiac telesurgery.

More broadly, the company said 173 telesurgeries have now been completed worldwide using the SSI Mantra platform.

In Guyana, three robotic procedures were completed on the inaugural day of the national robotic surgery program. SS Innovations said it received regulatory approval for the SSI Mantra from Guyana’s government analyst-food and drug department in May 2026.

The system now has regulatory approval in 14 countries: Colombia, Ecuador, Guatemala, Guyana, India, Indonesia, Iraq, Kenya, Nepal, Oman, the Philippines, Sri Lanka, Ukraine and the United Arab Emirates. The market has reacted to these announcements by moving the company's shares -9.05% to a price of $3.92. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS